Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
---|---|---|---|---|---|---|---|---|---|
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €16.6→€20 | ― | 4.00% | Upgraded | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €209 | ― | 25.80% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €22 | ― | 4.30% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €37.5→€44 | ― | 7.70% | Upgraded | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €64 | ― | 3.80% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL €12.8→€7.5 | ― | 4.40% | Downgraded | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €110→€103 | ― | 0.10% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €80→€92.5 | ― | 0.10% | Reiterated | |||||
Covivio SA | BUY €62→€60 | ― | -8.30% | Reiterated | Covivio (COV:FP) PT Lowered to EUR60 at JPMorganJPMorgan analyst Vanessa Guy lowered the price target on Covivio (COV:FP) to EUR60.00 (from EUR62.00) while maintaining a Overweight rating. | ||||
Klepierre (ex Compagnie Fonciere Klepierre) | SELL €30→€31 | ― | -8.30% | Reiterated | Klepierre (LI:FP) (KLPEF) PT Raised to EUR31 at JPMorganJPMorgan analyst Vanessa Guy raised the price target on Klepierre (LI:FP) (OTC: KLPEF) to EUR31.00 (from EUR30.00) while maintaining a Underweight rating. | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €2,165→€2,461 | ― | 11.70% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €780→€755 | ― | 7.50% | Reiterated | ||||
Manos MastorakisDeutsche Bank Not Ranked | Ipsen | BUY €116→€122 | ― | ― | Upgraded | Deutsche Bank Upgrades Ipsen SA (IPN:FP) (IPSEY) to BuyDeutsche Bank analyst Manos Mastorakis upgraded Ipsen SA (IPN:FP) (OTC: IPSEY) from Hold to Buy with a price target of EUR122.00 (from EUR116.00). | |||
DANONE SA | BUY €78 | ― | -0.10% | Reiterated | UBS Sticks to Their Buy Rating for DANONE SA (0KFX) | ||||
Sodexo SA | HOLD €65→€62 | ― | -1.00% | Reiterated | Sodexo SA (0J3F) Gets a Hold from Jefferies | ||||
DANONE SA | BUY €85 | ― | -1.60% | Reiterated | J.P. Morgan Reaffirms Their Buy Rating on DANONE SA (0KFX) | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €151→€148 | ― | 0.30% | Reiterated | |||||
LVMH Moet Hennessy Louis Vuitton | BUY €750 | ― | -5.20% | Reiterated | LVMH Moet Hennessy Louis Vuitton (0HAU) Gets a Buy from RBC Capital | ||||
Kering SA | HOLD €240 | ― | -5.20% | Reiterated | RBC Capital Reaffirms Their Hold Rating on Kering SA (0IIH) | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €250 | ― | 2.00% | Upgraded | |||||
TotalEnergies SE | BUY €70 | ― | -1.70% | Reiterated | J.P. Morgan Sticks to Its Buy Rating for TotalEnergies SE (TTE) | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €190 | ― | 4.00% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €60 | ― | 19.20% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €66→€58 | ― | 14.30% | Reiterated | ||||
Rexel SA | HOLD €28→€27 | ― | -9.50% | Reiterated | Rexel SA (RXL:FP) (RXLSF) PT Lowered to EUR27 at JPMorganJPMorgan analyst Akash Gupta lowered the price target on Rexel SA (RXL:FP) (OTC: RXLSF) to EUR27.00 (from EUR28.00) while maintaining a Neutral rating. | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €30→€27 | ― | 14.30% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €120 | ― | 13.00% | Reiterated | ||||
Fnac Darty SA | BUY €36 | ― | 0.00% | Initiated | BNP Paribas Exane Starts Fnac Darty SA (FNAC:FP) at OutperformBNP Paribas Exane analyst Geoffrey D'Halluin initiates coverage on Fnac Darty SA (FNAC:FP) with a Outperform rating and a price target of EUR36.00. | ||||
Maisons du Monde SA | HOLD €3 | ― | 0.00% | Initiated | BNP Paribas Exane Starts Maisons du Monde SA (MDM:FP) at NeutralBNP Paribas Exane analyst Geoffrey D'Halluin initiates coverage on Maisons du Monde SA (MDM:FP) with a Neutral rating and a price target of EUR3.00. | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €187→€150 | ― | 11.20% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €1.6 | ― | 12.00% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €10 | ― | 2.90% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €140→€175 | ― | 31.70% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €120 | ― | 11.90% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €235→€265 | ― | 31.70% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €114→€101 | ― | 1.80% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €290 | ― | 7.90% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €28.7 | ― | 3.10% | Downgraded | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL €9→€11 | ― | 6.00% | Initiated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €4.4→€2.9 | ― | 4.40% | Downgraded | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €41.7 | ― | 3.10% | Reiterated | |||||
Nanobiotix | BUY €10 | ― | -2.00% | Reiterated | Positive Clinical Data and Strategic Partnerships Drive Buy Rating for Nanobiotix | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €103→€97 | ― | 2.70% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €250 | ― | 10.70% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €3,000 | ― | 7.70% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €845→€800 | ― | 7.70% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €230→€205 | ― | 7.70% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €9.5→€10.35 | ― | 25.80% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €131→€147 | ― | 14.70% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €7→€9 | ― | 5.00% | Reiterated |